Higher Medicine
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
Higher Medicine is advancing clinics-ready small molecules for pediatric and neurodegenerative disorders, starting with Kabuki syndrome and Friedreich’s ataxia. Our lead programs—an LSD1 inhibitor and a p38 MAP kinase inhibitor—are supported by substantial safety and clinical data, enabling a de-risked entry into Phase 2a trials by 2026. With $200K raised and $2.1M in soft commitments, we’re closing a $2M pre-seed round to complete IND-enabling steps. Backed by top-tier advisors and collaborators at Johns Hopkins and UPenn, we offer a capital-efficient path to near-term proof-of-concept data and long-term impact across autism, Alzheimer’s, and health span extension.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}